Form 4: Corbus Pharma Director Yong Ben Receives Equity Grant

Corbus Pharmaceuticals Holdings, Inc. director Yong Ben was granted 3,800 restricted stock units and 12,300 stock options.

Summary

• Director Yong Ben of Corbus Pharmaceuticals Holdings, Inc. received an equity grant on May 19, 2026.
• The grant included 3,800 restricted stock units (RSUs) and 12,300 stock options.
• The RSUs will settle in shares of common stock, par value $0.0001, and will vest 100% on the one-year anniversary of the grant date (May 19, 2027).
• The stock options have an exercise price of $9.15 and will vest 100% on the one-year anniversary of the grant date (May 19, 2027).
• Following these transactions, Yong Ben beneficially owns 11,383 shares of common stock, which includes 8,600 previously reported unvested RSUs.
• The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard corporate governance practices where director compensation includes equity, aligning interests with shareholders.

Positives

• The grant of restricted stock units and stock options aligns the director's interests with those of shareholders, promoting long-term value creation.
• Equity compensation is a standard practice for retaining and incentivizing key personnel, including directors.

Future Outlook

The vesting schedules for the granted restricted stock units and stock options indicate future beneficial ownership for the director, contingent on continued service and the company's performance.

Industry Context

StockSavvy.ai notes that equity grants to directors are a common practice across the biotechnology and pharmaceutical industries, serving to align leadership incentives with long-term shareholder value creation. This particular grant is consistent with typical compensation structures for non-executive directors.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• Vesting of 3,800 restricted stock units on May 19, 2027.
• Vesting of 12,300 stock options on May 19, 2027.

Key Dates

Keywords

Corbus Pharmaceuticals, CRBP, Yong Ben, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Compensation, Director Compensation